Back to News
Nov 6, 2025 8:00 PM

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

The announcement, made during a White House press briefing, marks a potential game-changer in the escalating obesity treatment market.

Under the new deal, Medicare and Medicaid will begin covering obesity medications, including GLP-1 drugs,  short for glucagon-like peptide-1 receptor agonists– starting in April 2026.

Patients will see monthly out-of-pocket costs ranging from $50 to $350, depending on dosage and insurance coverage, a sharp reduction from the $1,000-plus price tags many currently face.

Eli Lilly CEO Says ‘Turning Point’ In Obesity Fight

"This action today will really begin to change the arc of chronic disease in our country," Dave Ricks, CEO of Eli Lilly, said, adding that the reduced cost "opens ...